presentation1_What Matters Most to Lung Cancer Patients? A Qualitative Study in Italy and Belgium to Investigate Patient Preferences.pdf
Background: The potential value of patient preference studies has been recognized in clinical individual treatment decision-making between clinicians and patients, as well as in upstream drug decision-making. Drug developers, regulators, reimbursement and Health Technology Assessment (HTA) bodies are exploring how the use of patient preference studies could inform drug development, regulatory benefit risk-assessment and reimbursement decisions respectively. Understanding patient preferences may be especially valuable in decisions regarding Non-Small Cell Lung Cancer (NSCLC) treatment options,... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Text |
Erscheinungsdatum: | 2021 |
Schlagwörter: | Pharmacology / Basic Pharmacology / Clinical Pharmacology and Therapeutics / Clinical Pharmacy and Pharmacy Practice / Pharmaceutical Sciences / Pharmacogenomics / Toxicology (incl. Clinical Toxicology) / Pharmacology and Pharmaceutical Sciences not elsewhere classified / patient preferences / drug decision-making / drug development / patient-centered research / lung cancer / benefit-risk assessment / focus group discussions |
Sprache: | unknown |
Permalink: | https://search.fid-benelux.de/Record/base-26613952 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.3389/fphar.2021.602112.s001 |